Japan’s advanced pharmaceutical industry is renowned, but until recently had relatively little involvement with the development of products to serve the developing world. The Global Health Innovative Technology Fund (GHIT) is aiming to change that. A public-private partnership fund, GHIT invests in the development of drugs, diagnostics and vaccines for malaria, TB, HIV/AIDS and neglected tropical diseases. Camilla Burkot recently sat down with GHIT’s CEO, Dr BT Slingsby, to discuss the fund’s origins, the kinds of partnerships and products it is fostering, and the impact that these can be expected to have in the coming years.
Japan’s advanced pharmaceutical industry is renowned, but until recently had relatively little involvement with the development of products to serve the developing world. The Global Health Innovative Technology Fund (GHIT) is aiming to change that. A public-private partnership fund, GHIT invests in the development of drugs, diagnostics and vaccines for malaria, TB, HIV/AIDS and neglected tropical diseases. Camilla Burkot recently sat down with GHIT’s CEO, Dr BT Slingsby, to discuss the fund’s origins, the kinds of partnerships and products it is fostering, and the impact that these can be expected to have in the coming years.